HIMSS recognizes first 7 vendors to earn ConCert by HIMSS mark

HIMSS will recognize seven health IT vendors for developing ConCert by HIMSS™ certified products. Gaining the ConCert by HIMSS mark requires a rigorous testing program to demonstrate that the product is interoperable with other products and can enable the secure, reliable, efficent and seamless transfer of data within and across organizational and state boundaries.

The seven vendors are:

  • Caradigm
  • Cerner
  • Corepoint Health
  • iPatientCare
  • MEDfx
  • NextGen Healthcare
  • Qvera

Introduced at HIMSS15, ConCert by HIMSS offers a vendor-independent seal of approval for EHR, health information services provider (HISP) and health information exchange (HIE) systems. Governed by HIMSS, ConCert by HIMSS is built on the work of the EHR/HIE Interoperability Workgroup and IHE USA. ICSA Labs serves as the testing and certification body for this effort. Stella Technology designed the program’s Interoperability Test Tool.

“In less than a year, seven vendors have responded successfully to the exciting opportunity to advance products meeting Concert by HIMSS’ rigorous standards,” said Joyce Sensmeier, vice president, informatics, HIMSS North America. “As a result, their certified products will be in the spotlight at the HIMSS Interoperability Showcase’s Testing and Certification Vignette, where HIMSS16 attendees will be able to see firsthand how certified products facilitate data exchange leading to the best point-of-care decisions and most optimal patient outcomes.”

“The development of these seven certified products is another important stride toward health information exchange across health system and state boundaries,” said George Japak, managing director, ICSA Labs. “ICSA Labs looks forward to the growth of the Concert by HIMSS program as interoperability continues to climb by increasing numbers of patients and providers.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup